South Dakota Investment Council Has $19.39 Million Stake in Solventum Corporation $SOLV

South Dakota Investment Council increased its position in Solventum Corporation (NYSE:SOLV) by 3.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 255,625 shares of the company’s stock after buying an additional 8,960 shares during the period. South Dakota Investment Council’s holdings in Solventum were worth $19,387,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SOLV. Independent Franchise Partners LLP lifted its stake in Solventum by 263.1% in the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after acquiring an additional 4,217,570 shares during the last quarter. Davis Selected Advisers raised its holdings in shares of Solventum by 0.8% during the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock valued at $402,110,000 after purchasing an additional 41,524 shares in the last quarter. Boston Partners raised its holdings in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after purchasing an additional 1,691,565 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Solventum by 3.3% in the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after purchasing an additional 58,373 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Solventum by 2.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock valued at $89,268,000 after purchasing an additional 24,762 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have commented on SOLV. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. Morgan Stanley raised Solventum from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Wall Street Zen downgraded Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Piper Sandler reiterated an “overweight” rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Finally, UBS Group initiated coverage on shares of Solventum in a research report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $84.89.

Solventum Stock Performance

SOLV opened at $69.04 on Monday. The firm has a market capitalization of $11.97 billion, a P/E ratio of 31.96, a price-to-earnings-growth ratio of 2.80 and a beta of 0.49. The stock’s 50 day moving average price is $72.41 and its two-hundred day moving average price is $72.38. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The company had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same period in the previous year, the company earned $1.56 earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.